Results 61 to 70 of about 2,846 (197)

Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment

open access: yesImmunology &Cell Biology, Volume 104, Issue 7, Page 711-728, August 2026.
Three interconnected processes in glioblastoma (GBM) biology: initiation, stratification, and immunosuppression. 1) Initiation: GBM initiation is proposed to occur through migration of TERT mutation‐bearing neural stem cells from the subventricular zone to the frontal and temporal cortices, where a subsequent oncogenic transformation drives their ...
Emerson Achari   +6 more
wiley   +1 more source

Cilengitide induces Src and FAK phosphorylation.

open access: yes, 2013
(a) Western blotting analysis of Src phosphorylation at Y529 and Y419 and total Src in HUVEC grown on fibronectin and exposed for 10 minutes to EMD135981, cilengitide (10 µM each) and CGP77675 (2.5 µM) as indicated.
Gian Carlo Alghisi (374631)   +2 more
core   +1 more source

The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma

open access: yes, 2008
Inhibitors of a, integrins have been developed as anti-angiogenic agents for cancer therapy and, among them, cyclic RGD-containing pentapeptides, such as cilengitide, are the most commonly used integrin antagonists.
DORIO, ANNALISA SUSANNA   +6 more
core   +3 more sources

NIR‐II Fluorescence Surgical Navigation for Gastric Cancer: Systematic Preclinical Validation Toward Clinical Application

open access: yesAggregate, Volume 7, Issue 7, July 2026.
A systematic preclinical workflow demonstrates the utility of an integrin‐targeted NIR‐II fluorescent probe for gastric cancer resection. This zwitterionic molecular tracer minimizes nonspecific background signals to achieve high contrast imaging.
Xiaolong Liu   +10 more
wiley   +1 more source

SARS-CoV-2 uses major endothelial integrin αvβ3 to cause vascular dysregulation in-vitro during COVID-19.

open access: yesPLoS ONE, 2021
The unprecedented global COVID-19 pandemic has prompted a desperate international effort to accelerate the development of anti-viral candidates.
Danielle Nader   +3 more
doaj   +1 more source

Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model

open access: yes, 2022
Integrins play an important role in multiple stages of tumor progression and metastasis. Previous studies have shown synergistic effects of combined αvβ6-integrin and αvβ8-integrin inhibitors with immunotherapy.
Xianglin Yuan (220063)   +6 more
core   +1 more source

Integrin α5β1‐mediated multicellular crosstalk in the tumor microenvironment drives bladder cancer progression and reveals targetable vulnerabilities

open access: yesiMetaOmics, Volume 3, Issue 2, June 2026.
Integrating multiplexed immunofluorescence, animal models, and clinical samples, our single‐cell and spatial atlas maps tumor microenvironment evolution during bladder cancer (BCa) progression. We reveal that stemness‐associated tumor cells (SDC1+), POSTN+ myofibroblastic cancer‐associated fibroblasts (mCAFs), and immunosuppressive monocytic myeloid ...
Ting Liang   +13 more
wiley   +1 more source

Ovarian Matrisome Dynamics and αvβ3‐Mediated Regulation in Early Follicular Development

open access: yesAdvanced Science, Volume 13, Issue 29, 22 May 2026.
The matrisome undergoes dynamic remodeling during early follicular development. Integrin αvβ3 mediates matrisome signals, regulating primordial follicle activation/atresia and secondary follicle growth via Hippo/mTOR pathways, with conserved roles in human ovaries, offering therapeutic targets for ovarian disorders.
Tong Wu   +12 more
wiley   +1 more source

Proposed model of cilengitide effects on endothelial cells.

open access: yes, 2013
Cilengitide acts on αVβ3-expressing endothelial cells in three ways: 1, it suppresses αVβ3-dependent adhesion by directly inhibiting αVβ3-ligand-binding function; 2, it interferes with β1 integrin-mediated cell adhesion through a transdominant negative ...
Gian Carlo Alghisi (374631)   +2 more
core   +1 more source

Cilengitide: A Novel Integrin Antagonist, in Malignant Glioma [PDF]

open access: yes, 2010
Cilengitide is a novel cyclic peptide that demonstrates anti-integrin activity. In laboratory studies, cilengitide binds with high affinity to the intergrins αvβ3 and αvβ5. It blocks proliferation of cells expressing this class of integrins and results in antiangiogenic and antitumor activity in animal models. Cilengitide has found a niche for clinical
openaire   +1 more source

Home - About - Disclaimer - Privacy